Real-world prophylactic usage of recombinant factor VIII Fc in Sweden: A report from the Swedish national registry for bleeding disorders

Haemophilia. 2021 Jul;27(4):e554-e558. doi: 10.1111/hae.14316. Epub 2021 May 13.

Margareta Holmström^{1

2}, Elsa Olsson¹, Jan Astermark^{3

4}, Malin Axelsson⁴, Anna Olsson⁵, Linda Myrin Westesson⁵, Aletta Falk⁶, Johan Szamosi⁶, Karin Sennfält⁶

¹ Coagulation Unit, Dept of Hematology, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden.
² Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden.
³ Department of Translational Medicine, Lund University, Malmö, Sweden.
⁴ Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Malmö, Sweden.
⁵ Department of Medicine, Region Västra Götaland, Sahlgrenska University Hospital, Gothenburg, Sweden.
⁶ Swedish Orphan Biovitrum AB, Stockholm, Sweden.

No abstract available

Keywords: extended half-life; factor consumption; haemophilia A; joint health; rFVIIIFc.

Publication types